Skip to main content

Table 3 Summary of the meta-analyses done to assess therapeutic efficacy of umbilical cord-derived stem cell transplantation in subjects who received intervention compared to control subjects who did not receive that intervention

From: Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study

Study name and year

Number of subjects

SC group

Number of subjects

Control group

Study weight

SMD

Lower CI

Upper CI

Type of DM

Type of UC-SC

Mean

SD

Mean

SD

HbA1c%

 Hu et al., 2013

15

6.100

1.100

14

7.400

1.900

18.7

− 0.821

− 1.580

− 0.063

T1DM

WJ-MSCs

 Hu et al., 2016

31

6.000

0.700

30

7.100

0.800

22.5

− 1.446

− 2.010

− 0.883

T2DM

WJ-MSCs

 Cai et al., 2016

21

7.500

1.000

21

8.800

0.900

20.4

− 1.341

− 2.010

− 0.671

T1DM

WJ-MSCs

 Chen et al., 2016

6

6.820

0.530

6

7.820

0.310

9.6

− 2.125

− 3.541

− 0.710

T2DM

WJ-MSCs

 Haller et al., 2013

10

7.100

1.290

5

7.400

0.400

13.5

− 0.258

− 1.335

0.820

T1DM

UCB

 Giannopoulou et al., 2013

7

7.250

0.440

10

7.225

1.070

15.2

0.027

− 0.939

0.993

T1DM

UCB

C-peptide levels (ng/ml)

 Hu et al., 2013 a

15

1.350

0.230

14

0.810

0.300

16.9

1.973

1.085

2.861

T1DM

WJ-MSCs

 Hu et al., 2016 a

31

2.660

0.330

30

1.670

0.250

17.3

3.331

2.555

4.106

T2DM

WJ-MSCs

 Cai et al., 2016 a

21

0.060

0.030

21

0.030

0.020

17.7

1.154

0.501

1.808

T1DM

WJ-MSCs

 Chen et al., 2016 c

6

0.700

0.380

6

0.220

0.130

15.4

1.560

0.267

2.852

T2DM

WJ-MSCs

 Haller et al., 2013 b, *

10

0.163

0.181

5

0.207

0.211

16.2

− 0.217

− 1.293

0.859

T1DM

UCB

 Giannopoulou et al., 2013 b

7

0.390

0.388

10

1.032

0.800

16.5

− 0.914

− 1.928

0.099

T1DM

UCB

  1. aFasting C-peptide
  2. bStimulated peak C-peptide
  3. cStimulated early phase C-peptide secretion function ΔCP30/ΔG30
  4. *Measuring unit; pmol/L